References

Hypertrophic Cardiomyopathy

10.1056/nejmra2413445 · 2025 · External reference

2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

10.1161/cir.0000000000001250 · 2024 · External reference

Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction

10.1161/circulationaha.106.644682 · 2006 · External reference

Atrial Fibrillation in Hypertrophic Cardiomyopathy

10.1016/j.jacadv.2024.101210 · 2024 · External reference

Clinical Course and Management of Hypertrophic Cardiomyopathy

10.1056/nejmra1710575 · 2018 · External reference

Ischemic Stroke in Patients With Hypertrophic Cardiomyopathy According to Presence or Absence of Atrial Fibrillation

10.1161/strokeaha.121.034213 · 2022 · External reference

Prognosis of hypertrophic cardiomyopathy patients with atrial fibrillation: A multicenter cohort study with real-world data

10.1016/j.hrtlng.2026.102790 · 2026 · External reference

Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: A propensity score-matched cohort

10.1016/j.jtcvs.2018.08.062 · 2019 · External reference

Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy: A Word of Balance

10.1016/j.jacc.2017.06.011 · 2017 · External reference

Ventricular Septal Myectomy Decreases Long-Term Risk for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy

10.1016/j.amjcard.2022.05.032 · 2022 · External reference

Clinical Significance of Postoperative Atrial Fibrillation in Hypertrophic Cardiomyopathy Patients Undergoing Septal Myectomy

2023 · External reference

Myectomy versus alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy

10.1093/icvts/ivaa075 · 2020 · External reference

Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry

10.1161/circulationaha.124.069378 · 2024 · External reference

Alcohol Septal Ablation versus Septal Myectomy Treatment of Obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis

10.3390/jcm9103062 · 2020 · External reference

Alcohol septal ablation versus surgical septal myectomy of obstructive hypertrophic cardiomyopathy: systematic review and meta-analysis

10.1093/ejcts/ezad043 · 2023 · External reference

TriNetX Dataworks-USA: Overview of a Multi-Purpose, De-Identified, Federated Electronic Health Record Real-World Data and Analytics Network and Comparison to the US Census

10.1002/pds.70198 · 2025 · External reference

A global federated real-world data and analytics platform for research

10.1093/jamiaopen/ooad035 · 2023 · External reference

Pericardial Effusion Provoking Atrial Fibrillation After Cardiac Surgery: JACC Review Topic of the Week

10.1016/j.jacc.2022.04.029 · 2022 · External reference

Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data

10.1016/j.jacc.2007.06.054 · 2007 · External reference

Alcohol and Atrial Fibrillation: A Sobering Review

10.1016/j.jacc.2016.08.074 · 2016 · External reference

Treatment Strategies for Hypertrophic Cardiomyopathy: Alcohol Septal Ablation and Procedural Step-by-Step Technique

10.1016/j.amjcard.2023.10.064 · 2024 · External reference

Risk of arrhythmic events after alcohol septal ablation for hypertrophic cardiomyopathy using continuous implantable cardiac monitoring

10.1016/j.hrthm.2020.08.013 · 2021 · External reference

Altered atrial electrical restitution and heterogeneous sympathetic hyperinnervation in hearts with chronic left ventricular myocardial infarction: implications for atrial fibrillation

10.1161/01.cir.0000080327.32573.7c · 2003 · External reference

Early and late post-operative arrhythmias after surgical myectomy: 45 years of follow-up

10.1016/j.ijcard.2020.11.055 · 2021 · External reference

Long-Term Continuous Monitoring of New-Onset Atrial Fibrillation After Coronary Artery Bypass Grafting

10.1001/jama.2025.14891 · 2025 · External reference

Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy: JACC: Heart Failure State-of-the-Art Review

10.1016/j.jchf.2023.04.018 · 2023 · External reference

Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort

10.1016/j.jchf.2023.09.028 · 2024 · External reference

Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM

10.1161/circulationaha.124.072445 · 2025 · External reference

New and recurrent atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy receiving mavacamten

10.1016/j.hrthm.2026.04.033 · 2026 · External reference

Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM

10.1016/j.jchf.2025.03.040 · 2025 · External reference

Cardiac Myosin Inhibitors and Incident Atrial Fibrillation in Hypertrophic Cardiomyopathy: Systematic Review and Meta-Analysis

10.1111/jce.70317 · 2026 · External reference

Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive Hypertrophic Cardiomyopathy

10.1016/j.jacc.2022.02.032 · 2022 · External reference

Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation: The HCM-AF Score

10.1161/circep.120.009796 · 2021 · External reference

Subclinical atrial fibrillation and the risk of stroke

10.1056/nejmoa1105575 · 2012 · External reference